 Connection
Robert Breeze to Antiparkinson Agents
This is a "connection" page, showing publications Robert Breeze has written about Antiparkinson Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.125 |
|
|
|
-
Freed CR, Rosenberg NL, Schneck SA, Breeze RE. Improved drug responsiveness following fetal tissue implant for Parkinson's disease. Neurochem Int. 1992 Mar; 20 Suppl:321S-327S.
Score: 0.094
-
Trott CT, Fahn S, Greene P, Dillon S, Winfield H, Winfield L, Kao R, Eidelberg D, Freed CR, Breeze RE, Stern Y. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology. 2003 Jun 24; 60(12):1938-43.
Score: 0.013
-
Freed CR, Breeze RE, Rosenberg NL, Schneck SA. Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease. Replacing failed nerve terminals. Adv Neurol. 1993; 60:721-8.
Score: 0.006
-
Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, Lone T, Zhang YB, Snyder JA, Wells TH, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 1992 Nov 26; 327(22):1549-55.
Score: 0.006
-
Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, Grafton ST, Mazziotta JC, Eidelberg D, Rottenberg DA. Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. Prog Brain Res. 1990; 82:715-21.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|